Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Subcutaneous XH-02 in Adult Hypoparathyroidism
NCT07530705Phase 2Suspended
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XH-02 in hypoparathyroidism, sponsored by Peking Union Medical College Hospital. Started Nov 2025; status: suspended.
02
Drugs
XH-02
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT07530705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530705.